Illinois Court Rules for Defendant in Prenatal Monitoring Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Fitch, Even, Tabin and Flannery, LLP v. Tammy E. Dorsey, James R. Balman, and Prenatal-Hope, Inc. |
| Case Number | No. 1:25-cv-03141 |
| Court | Northern District of Illinois, Chief Judge Sharon Johnson Coleman |
| Duration | March 25, 2025 – February 23, 2026 335 days |
| Outcome | Defendant Win — No Damages to Plaintiff |
| Patents at Issue | |
| Accused Products | Apparatus and method for determining physiological parameters of an infant in utero |
Case Overview
The Parties
⚖️ Plaintiff
A prominent Chicago-based intellectual property law firm, acting as plaintiff, signaling a direct IP ownership or enforcement interest.
🛡️ Defendant
The accused parties in this dispute, with Prenatal-Hope, Inc. likely operating in the prenatal diagnostics or monitoring space.
Patents at Issue
This case centered on U.S. Patent No. US11622705B2, covering an apparatus and method for determining physiological parameters of an infant in utero — a critical technology in the growing market for non-invasive fetal health assessment.
- • US11622705B2 — Apparatus and method for determining physiological parameters of an infant in utero
Designing a prenatal monitoring device?
Check if your technology might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered a verdict in favor of defendants Tammy E. Dorsey, James R. Balman, and Prenatal-Hope, Inc., and against plaintiff Fitch, Even, Tabin and Flannery, LLP. No damages award to plaintiff was recorded, making this a significant defendant-favorable outcome in medical device patent litigation.
Key Legal Issues
While the specific legal reasoning is undisclosed, a defendant-favorable outcome in a patent infringement action can arise from several pathways: a finding of non-infringement, successful challenges to patent invalidity (e.g., due to obviousness or anticipation), or a claim construction adverse to the plaintiff’s assertions. For medical device method patents, the precise scope of functional claim language often proves dispositive.
Freedom to Operate (FTO) Analysis in Prenatal Monitoring
This case highlights critical IP risks in the rapidly evolving prenatal monitoring space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 65 related patents in this technology space
- See which companies are most active in prenatal monitoring IP
- Understand claim construction patterns for physiological measurement
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
In-utero physiological monitoring methods
65 Related Patents
In prenatal health tech space
Design-Around Options
Available for most claim interpretations
✅ Key Takeaways
Defendant prevailed in a medical device method patent (US11622705B2) infringement action in N.D. Illinois within 335 days, suggesting a potentially early dispositive resolution.
Search related case law →Claim construction for physiological monitoring method claims remains a critical battleground, impacting both infringement and validity.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. US11622705B2 (Application No. US17/555256), covering an apparatus and method for determining physiological parameters of an infant in utero.
The Northern District of Illinois ruled in favor of defendants Tammy E. Dorsey, James R. Balman, and Prenatal-Hope, Inc., and against plaintiff Fitch, Even, Tabin and Flannery, LLP in this infringement action.
The outcome may embolden defendants in similar cases to mount stronger invalidity and non-infringement defenses, and signals that courts will rigorously apply claim construction standards to physiological monitoring method patents.
The case was resolved within approximately 335 days from filing to closure, which is significantly faster than the national median for patent litigation at the district court level, typically exceeding 18-24 months.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- U.S. District Court for the Northern District of Illinois — Case No. 1:25-cv-03141
- U.S. Patent and Trademark Office — Patent Full-Text Database (US11622705B2)
- Cornell Legal Information Institute — 35 U.S.C. § 103 (Obviousness)
- Federal Judiciary CMECF System — Accessing Court Records
- PatSnap — IP Intelligence Solutions for Medical Devices
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.